News

Mission’s wholly-owned subsidiary, ProSolus Inc., offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal (through the skin) drug delivery products to treat a variety

The per share price will be based on the 20-day volume weighted average price (VWAP) of the Company’s Common Stock upon the closing of the acquisition. CBMG will

The Affordability is Access Act – legislation was introduced by US Senator Barbara Boxer along with Senator Patty Murray, Ranking Member of the Senate Health, Education, Labor, and

Haemophilia A is a rare chronic bleeding disorder, which leads to inadequate clotting of blood in response to any type of injury or surgery and about 30% of

RORgamma is a master control switch of immune system activation to treat a broad range of cancers and Lycera has discovered selective and potent oral agonists that target

Exovita Biosciences holds the option to an exclusive, worldwide license for the patent-pending technology developed by Kristina Antonia Trujillo, a research assistant professor in UNM’s Department of Biochemistry

Currently, tesamorelin is not indicated for either of these conditions and the company’s role in this collaboration will include supplying the drug to the MGH. The US National

The company has been developing BB3, which is a proprietary small molecule that mimics the activity of hepatocyte growth factor (HGF). In preclinical models of AKI, BB3 showed

Earlier, the company had announced plans to submit the multi-center, randomized Phase II trial completed last year as one of two pivotal trials required for a new drug